UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a…
Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
– New findings demonstrate a 72% HI-E response rate at Week 16…
TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
December 06, 2025 17:30 ET Â | Source: TScan Therapeutics, Inc. Treatment arm…
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 06, 2025 17:30 ET  | Source: Fulcrum Therapeutics, Inc. ― Clear…
Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinsons Disease
December 05, 2025 21:00 ET Â | Source: Cerevance, Inc. Phase 2 results…
GENESIS MOTOR EUROPE ANNOUNCES MAXIMILIAN KALBFELL AS NEW HEAD OF MARKETING
Genesis Motor Europe strengthens its executive team, with the appointment of Maximilian…
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT for Parkinsons Disease
December 05, 2025 08:00 ET Â | Source: Amneal Pharmaceuticals LLC Interim data…
NobleAI Appoints Alex Wang as Chief Executive Officer to Lead Next Phase of Growth and Innovation
SAN FRANCISCO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- NobleAI, the leader in…
Plume Appoints Lorie Boyd as Chief People Officer
Boyd brings deep HR and workforce management experience from Turo and Zendesk…
Yatra Strengthens Leadership for Next Phase of Growth
Elevates Co-Founder Dhruv Shringi to Executive Chairman; Appoints Siddhartha Gupta as CEONEW…